Consumption of chewing tobacco alters the serum metal contents in pregnant women at Tandojam and adjoining areas.

Chewing tobacco may play a contributing role in complications during pregnancy as it contains various kinds of toxic metals such as lead (Pb), cadmium (Cd), cobalt (Co), manganese (Mn), chromium (Cr), and can cause alteration in serum metal concentration. Hence, the present study aimed to explore the effects of chewing tobacco consumption on serum metal contents in pregnant women. A total number of 200 chewing tobacco consumer pregnant women and 200 age-matched non-consumer pregnant women were selected for the study from the outpatient department of gynaecology at Rural Health Centre Tandojam, Pakistan. After obtaining the sociodemographic characteristics of all participants, 10 ml of venous blood was also drawn for serum metal analysis by atomic absorption spectroscopy. Different chewing tobacco samples consumed by consumer pregnant women were collected from local shops of Tandojam, Pakistan. Drinking water samples from the residential areas of consumer and non-consumer pregnant women were prepared and analysed for the same metal contents. In present study, serum Pb, Cd, K and Co were found significantly increased in CPW as compared to NCPW. Serum Pb was found significantly increased in gutkha consumers in comparison to mainpuri consumers. Serum Pb, Cd, and Co were present with significantly increased concentration in serum of CPW who were taking canal and well water for drinking purpose when compared with NCPW. Significant negative strong correlation of serum Pb with K and Cr of drinking water and Na of chewing tobacco samples were observed. Strong positive correlation of serum Cd and Cr with Co of drinking water had been observed. Whereas, serum maternal Co was strongly negatively correlated with Mn of chewing tobacco samples, and serum Cu of CPW had a strong positive correlation with K and Cr of drinking water and Na of chewing tobacco samples. In conclusion, consumption of chewing tobacco alters the serum metal contents in pregnant women at Tandojam and adjoining areas, Pakistan.

Haemodialysis alters the serum metal contents in chronic kidney failure patients at hyderabad and adjoining areas.

Present study aimed to explore alterations of serum metal contents in patients of chronic kidney disease before and after haemodialysis (HD) compared to controls. For the levels of heavy metals in serum samples of kidney patients before and after HD belonging to different areas of Hyderabad and adjoining areas admitted at different hospitals of Hyderabad. In this study, the level of copper (Cu), zinc (Zn), chromium (Cr), iron (Fe) and manganese (Mn) in serum sample of kidney patients and controls have been investigated using Atomic Absorption Spectrophotometer (AAS). An increase in serum urea and serum creatinine levels in patients with chronic kidney disease (CKD) when compared to controls was observed and it was due to the decreased glomerular filtration in patients with CKD. The average of serum Cu and Cr were significantly high in pre-HD patients as compared to controls, reverse was found just in case of Mn and Fe. Serum Cu and Mn were significantly increased in post-HD patients when put next to the controls, whereas, serum Cr concentration was significantly decreased after HD in comparison to the controls. Concentration of serum Cu, Fe and Mn were significantly increased in post-HD patients as compared to the pre-HD patients. In conclusion, hemodialysis alters the serum metal contents in CKD patients. After the study, it is suggested that, serum metal contents before the dialysis session must be investigated more extensively to elucidate the alterations throughout the dialysis session and may be medicated accordingly.

Penetration and drug delivery of albumin nanoparticles into pancreatic multicellular tumor spheroids.

Albumin-based nanoparticles have been exploited as a useful carrier for the efficient delivery of anti-cancer drugs. In this study, albendazole was encapsulated into bovine serum albumin (BSA)-polycaprolactone (PCL) conjugates and the formed nanoparticles with a size about 100 nm were used to treat pancreatic carcinoma cells. In addition, two more types of albendazole-loaded BSA nanoparticles, 10 nm and 200 nm ones, were prepared using a desolvation method. The albendazole-loaded BSA nanoparticles were evaluated with both 2D cultured AsPC-1 cells and 3D multicellular tumor spheroids (MCTS). Their anti-tumor effects were also compared. BSA-PCL nanoparticles and 200 nm BSA nanoparticles showed noticeable cytotoxicity to 2D cultured AsPC-1 cells when compared to the free drug. The penetration of BSA-PCL nanoparticles and 200 nm BSA nanoparticles, especially the BSA-PCL nanoparticles, enabled effective delivery of albendazole into pancreatic MCTS. BSA-PCL nanoparticles also showed a better inhibition effect on the growth of pancreatic MCTS than the 200 nm counterpart. Although 10 nm BSA nanoparticles inhibited the growth of MCTS, the inhibitory effect was even less than that of free albendazole. In addition, it is also found that SPARC protein facilitates the penetration and drug delivery of albumin nanoparticle since treatment using anti-SPARC antibody decreased the efficacy of drug loaded BSA nanoparticles.

Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft model.

BACKGROUND: The poor prognosis of patients with drug resistant ovarian cancer and the lack of targeted therapy have raised the need for alternative treatments. Albendazole (ABZ) is an anti-parasite compound capable of impairing microtubule formation. We hypothesized that ABZ could be repurposed as a potential anti-angiogenic drug due to its potent inhibition of vascular endothelial growth factor (VEGF) in ovarian cancer with ascites. However, the poor aqueous solubility of ABZ limits its potential for cancer therapy. In this study, we have assembled ABZ with bovine serum albumin into nanoparticles with a size range of 7-10 nm (BSA-ABZ) and 200-250 nm (Nab-ABZ). We further examined the anticancer effects of ABZ carrying nanoparticles in ovarian cancer cells, in both in vitro and in vivo models. RESULTS: Drug release studies demonstrated that about 93% of ABZ was released from BSA-ABZ 10 nm in comparison to 83% from Nab-ABZ 200 nm at pH 7.4 in 8 days. In vitro cell proliferation studies showed that the BSA-ABZ 10 nm exhibited the highest killing efficacy of ovarian cancer cells with surprisingly least toxicity to healthy ovarian epithelial cells. Confocal microscopy and fluorescence activated cell sorting analysis (FACS) revealed more efficient internalization of the BSA-ABZ 10 nm by cancer cells. For in vivo studies, we examined the tumor growth, ascites formation and the expression of VEGF and secreted protein acidic and rich in cysteine (SPARC) in tumor samples and only VEGF in plasma samples. The BSA-ABZ 10 nm reduced the tumor burden significantly (p < 0.02) at a much lower drug dose (10 µg/ml) compare to free drug. Both formulations were capable of suppressing the ascites volume significantly (p < 0.05) and reducing the number of ascites cells. The expression of VEGF and SPARC was also reduced, which indicates the underlying therapeutic mechanism of the ABZ. CONCLUSION: Our data suggest that the BSA-ABZ may hold promise for the treatment and control of progression of ovarian cancer with ascites. However further studies are required to examine the efficacy of both the formulations in aggressive models of recurrent ovarian cancer with respect to particle size and dosing parameters.